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Background: The prevalence of extended-spectrum β-lactamase-producing Escherichia 
coli (ESBL-EC) in the community has increased worldwide due to multifactorial reasons. 
ESBL-EC bloodstream infection (BSI) complicates the decision for proper antimicrobial 
administration. In this multicenter study, we investigated the prevalence, risk factors, and 
molecular background of community-onset (CO) ESBL-EC BSI.
Methods: We included data for all episodes of ESBL-EC BSI of community origin from 
May 2016 to April 2017 obtained from the Korean national antimicrobial resistance sur-
veillance system, which comprises six sentinel hospitals. Data, including previous history 
of admission and use of antimicrobials and medical devices before BSI, were collected, 
along with microbiological analysis results.
Results: Among 1,189 patients with CO BSI caused by E. coli, 316 (27%) were identified 
as ESBL producers. History of admission, especially to a long-term care hospital (LTCH), 
and previous use of β-lactams/β-lactamase inhibitors, carbapenem, lincosamide, amino-
glycoside, and extended-spectrum cephalosporin were independent risk factors for CO 
ESBL-EC BSI; admission to an LTCH showed the highest odds ratio (3.8, 95% confidence 
interval 2.3–6.1). The most common genotype was CTX-M-15 (N=131, 41%), followed 
by CTX-M-14 (N=86, 27%). ST131 was the most common sequence type among ESBL-
EC groups (57%).
Conclusions: In Korea, 27% of CO E. coli BSI were caused by ESBL producers. From per-
spectives of empirical treatment and infection control, history of admission to an LTCH 
and antimicrobial use should be noted.
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erichia coli, Bloodstream infection, Prevalence, Risk factors, Molecular background
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INTRODUCTION
Extended-spectrum β-lactamase (ESBL)-producing Escherichia 
coli (ESBL-EC) has emerged as a major antimicrobial-resistant 
pathogen in the community worldwide [1]. Since ESBLs are typ-
ically plasmid-mediated, acquisition of plasmids containing 
these genes could confer resistance to antimicrobials [2]. SHV 
and TEM types were the first ESBLs identified in the late 1980s; 
however, the noble CTX-M type ESBL has dominated since the 
1990s [3]. Currently, ESBL-EC spread is mainly caused by the 
CTX-M-type ESBL-producing sequence type (ST) 131, which 
could pose a challenge for the management of community-on-
set (CO) infection [4]. The rapid dissemination of ESBL-EC is 
likely caused by several factors, such as misuse or overuse of 
antimicrobials in both humans and animals, international travel, 
and direct transmission within households and the community 
[5]. The elucidation of CO BSIs risk factors caused by antimi-
crobial-resistant bacteria is particularly important and can help 
develop specific strategies to prevent these infections and the 
spread of resistant bacteria. From a clinical perspective, this 
might help identify patients for whom empirical treatment 
should include coverage against antimicrobial-resistant infection 
[6]. As the epidemiological characteristics of ESBL-EC can show 
significant local variations, multicenter studies are important to 
obtain comprehensive knowledge of risk factors for infections 
caused by it. However, there are few large-scale studies of CO 
bloodstream infection (BSI) caused by ESBL-EC in Korea.
The incidence of CO ESBL-EC BSI was estimated to be 7.3% in 
Spain (2004–2006) [6], 6.9% in South Korea (2006–2009) [7], 
6.1% in the United States (2013) [8], and 55.5% in China (2013–
2014) [9]. However, the ESBL-EC incidence has increased among 
community-acquired urinary tract infections [10].
We investigated the prevalence, risk factors, and molecular 
background of CO ESBL-EC BSI in Korea using data from the 
Korean antimicrobial surveillance system Kor-GLASS. Kor-
GLASS is compatible with the Global Antimicrobial Resistance 
Surveillance System (GLASS) with respect to the standardization 
of antimicrobial resistance surveillance, in line with the previous 
Korean Antimicrobial Resistance Monitoring System [11]. The 
Kor-GLASS was established in May 2016, and the first 1-year 
assessment up to April 2017 was published in 2018 [12].
MATERIALS AND METHODS
Study design
Bacterial isolates and clinical data were collected for all epi-
sodes of CO ESBL-EC BSI (CO-BSI) from May 2016 to April 
2017 in six sentinel hospitals located throughout Korea, with a 
total of 5,194 beds (715 to 1,050 beds per hospital). During the 
study period, 1,510 patients were diagnosed as having E. coli 
BSI. Among them, 1,211 patients were identified as having a 
CO-BSI, which represented 80% of total E. coli BSI cases. We 
excluded 22 patients owing to lack of clinical information, leav-
ing 1,189 patients with CO-BSI for analysis. Data for clinical 
characteristics, including age, sex, intensive care unit (ICU) ad-
mission, underlying illness and its severity (Charlson morbidity 
index and sequential organ failure assessment [SOFA] score), 
from the electronic medical records of the sentinel hospitals 
were investigated [14, 15]. History of admission, antimicrobial 
use, and use of medical devices before BSI were acquired from 
the National Health Insurance claims database (HIRA claims 
data, http://nhiss.nhis.or.kr). Only the first bacterial isolate from 
each patient was collected for microbiological analysis, and sub-
sequent isolates were excluded. All isolates collected at the sen-
tinel hospitals were transferred to the Research Institute of Bac-
terial Resistance, Yonsei University College of Medicine, for mi-
crobiological assessments. 
Phenotypic confirmatory analysis and multilocus sequence 
typing (MLST) were conducted for each E. coli isolate at the 
analysis center. The study was approved by all local Institutional 
Review Boards of the six sentinel hospitals included in the study 
(National Health Insurance Service Ilsan Hospital, Yonsei Uni-
versity College of Medicine, Yonsei University Wonju College of 
Medicine, Chonnam National University School of Medicine, 
Inje University College of Medicine, and Chungbuk National 
University College of Medicine). The requirement for written in-
formed consent was waived. 
Definitions
CO-BSI includes healthcare-associated and community-ac-
quired infection but excludes hospital-acquired infection [13]. 
Cases for which the specimen was taken either from an outpa-
tient or from a patient hospitalized for <two days were included. 
If a patient was transferred from another hospital, the date of 
transfer was counted from the admission date at the previous 
hospital. History of admission was included when a patient was 
admitted to any hospital, excluding a nursing home, within three 
months before BSI. History of antimicrobial use was defined as 
any use of antimicrobials within three months before BSI.
Microbiological analysis
EC identification was performed with matrix-assisted laser de-
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sorption/ionization time-of-flight (MALDI-TOF) mass spectrome-
try (Bruker Biotyper, Bruker Daltonics GmbH, Bremen, Ger-
many) at the analysis center. Susceptibility was analyzed by the 
disk diffusion method on Mueller-Hinton agar (Difco Laborato-
ries, Detroit, MI, USA), according to the CLSI guidelines [14]. 
Genes encoding ESBLs (CTX-M-1, CTX-M-9, CTX-M-2, CTX-
M25, TEM, and SHV) were analyzed by PCR [15] and sequenc-
ing [16]. Briefly, bacterial DNA was extracted by the boiling lysis 
method, and the PCR was performed under the following ampli-
fication conditions: 94°C for 5 minutes, followed by 35 cycles at 
94°C for 30 seconds, then 59°C for 30 seconds (blaTEM), 61°C 
for 30 seconds (blaSHV), or 56°C for 20 seconds (blaCTX-M), and 
subsequently 72°C for 30 seconds, followed by a final extension 
at 72°C for 4 minutes using C1000TM Thermal Cycler (Bio-rad, 
Hercules, USA). PCR amplicons were purified using a QIAquick 
PCR purification kit (Qiagen, Hilden, Germany) and sequenced 
using an Applied Biosystems 3730xl DNA analyzer (Applied 
Biosystems, Foster City, CA) to identify the variant types of each 
family. MLST was performed on ESBL-EC isolates using seven 
conserved housekeeping genes (adk, fumC, gyrB, icd, mdh, 
purA, and recA) to identify the STs [17], with reference to the 
EC MLST database (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli).
Statistical analysis
Fisher’s exact test was used for univariate comparisons of cate-
gorical data. Variables that were not normally distributed, such 
as age, Charlson comorbidity index, and SOFA score, were ana-
lyzed by Mann–Whitney U test. Variables with P <0.05 from the 
univariate analysis were included in the multivariate logistic re-
gression model using the Backward Stepwise (Wald) method. 
We used two multivariate models because of collinearity be-
tween variables: history of admission to any hospital and to a 
long-term care hospital (LTCH). All P values were two-tailed and 
a P-value <0.05 was considered to indicate statistical signifi-
cane. All statistical analyses were performed using IBM SPSS 
Statistics for Windows software version 23.0 (IBM Corp., Ar-
monk, NY, USA).
RESULTS
The median age of the patients was 75 years [interquartile range 
(IQR) 63–81 years], and 39% patients (465/1,189) were males. 
The most prevalent underlying disease was diabetes mellitus 
(16%, 194/1,189). The median number of antimicrobials used 
within three months in patients with CO-BSI was 1 (IQR 0–3), 
and 61% of patients used one or more antimicrobials. The most 
frequently used antimicrobial was extended-spectrum cephalo-
sporin (29%, 342/1,189), followed by fluoroquinolone (24%) 
and β-lactams and β-lactamase inhibitors (19%).
Among E. coli causing CO-BSI episodes, 316 were identified 
as ESBL producers, resulting in an ESBL-EC prevalence of 27% 
(95% confidence interval, [CI] 24–29%). The clinical character-
istics of patients with CO-BSI caused by ESBL-EC and non-ESBL-
EC isolates are given in Table 1. Of the patients with ESBL-EC, 
62% (196/316) had a history of admission to any type of hospi-
tal, whereas 40% (346/873) of the non-ESBL-EC patients had a 
history of hospital admission. Admission to LTCH within three 
months of BSI was more common in the ESBL-EC group than in 
the non-ESBL-EC group (13% vs. 4%). There was no statistically 
significant difference in comorbidities, including diabetes, Charl-
son comorbidity index, and SOFA score, between the groups.
Univariate logistic regression showed that risk factors of ESBL-
EC BSI over those for non-ESBL-EC BSI included a history of 
ICU admission, history of admission to any hospital and to an 
LTCH, use of antimicrobials (β-lactams/β-lactamase inhibitors, 
fluoroquinolone, trimethoprim/sulfamethoxazole, lincosamide, 
glycopeptide, aminoglycoside, carbapenem, and cephalosporin, 
regardless of generation), and history of specific intervention 
(urinary catheterization, nasogastric tubes, and major surgery). 
 Multivariate analysis of risk factors associated with CO ESBL-
EC-BSI is described in Table 2. In the first model, we included a 
history of admission to any hospital as a variable, whereas the 
second model included history of admission to an LTCH instead 
of any hospital, because of recent concerns about antimicrobial 
resistance in LTCHs in Korea [21]. In the first model, indepen-
dent risk factors were history of admission to any hospital (odds 
ratio [OR] 1.6, 95% CI 1.1–2.2) and previous use of carbape-
nem (OR 2.7, 95% CI 1.7–4.3), lincosamide (OR 2.6, 95% CI 
1.3–5.3), aminoglycoside (OR 1.8, 95% CI 1.1–2.7), and ex-
tended-spectrum cephalosporin (OR 1.5, 95% CI 1.1–2.2). In 
addition to these variables, the second model identified the his-
tory of admission to an LTCH (OR 3.8, 95% CI 2.3–6.1) and 
previous use of β-lactams/β-lactamase inhibitors (OR 1.4, 95% 
CI 1.0–2.0) as significant independent risk factors.
All 316 isolates from patients with confirmed ESBL-EC BSI 
produced at least one CTX-M enzyme, including 168 (53%) iso-
lates of the CTX-M-1 group and 160 (51%) isolates of the CTX-
M-9 group; 12 isolates produced both CTX-M-1 and CTX-M-9 
enzymes. The most common genotype was CTX-M-15 (41%, 
N=131 of ESBL-EC), followed by CTX-M-14 (27%, N=86), 
CTX-M-27 (N=42), CTX-M-55 (N=28), CTX-M-17 (N=8), and 
CTX-M-24 (N=6). One isolate produced both CTX-M-15 and 
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TEM-30. MLST showed that the 316 ESBL-EC isolates belonged 
to 65 different STs, suggesting substantial genetic diversity 
among isolates. ST131 was more common in ESBL-EC (57%) 
than in non-ESBL-EC (8%) isolates (Table 3). 
DISCUSSION
Previous studies indicated that risk factors for CO ESBL-EC in-
fections were related to contact with healthcare facilities (such 
as recent admission to a hospital, residence in an LTCH), recent 
Table 1. Univariate analysis of risk factors associated with community-onset E. coli bloodstream infection
Variables ESBL (N=316) Non-ESBL (N=873) OR (95% CI) P
Age (yr), median (IQR) 75 (63–81) 74 (63–81) 0.595
Male 121 (38) 344 (39) 1.0 (0.8–1.2) 0.737
ICU admission 30 (10) 35 (4) 2.5 (1.5–4.2) <0.001
History of hospital admission 196 (62) 346 (40) 2.5 (1.9–3.2) <0.001
History of LTCH admission 41 (13) 37 (4) 3.4 (2.1–5.4) <0.001
Underlying disease
   End-stage renal disease 16 (5) 52 (6) 0.8 (0.5–1.5) 0.672
   Cerebrovascular disease 7 (2) 15 (2) 1.3 (0.5–3.2) 0.626
   Liver cirrhosis 9 (3) 29 (3) 0.9 (0.4–1.8) 0.852
   Chronic pulmonary disease 5 (2) 9 (1) 1.5 (0.5–4.6) 0.542
   Diabetes mellitus 62 (20) 132 (15) 1.4 (1.0–1.9) 0.075
   Cardiovascular disease 9 (3) 25 (3) 1.0 (0.5–2.2) 1.000
   Malignancy 40 (13) 120 (14) 0.9 (0.6–1.3) 0.701
Charlson comorbidity index (median, IQR) 4 (3–5) 4 (3–5) 0.905
SOFA score (median, IQR) 3 (1–5) 3 (1–5) 0.109
Antimicrobial use within previous three months
   Penicillin 19 (6) 50 (6) 1.1 (0.6–1.8) 0.888
   β-lactam/β-lactamase inhibitor 90 (29) 135 (16) 2.2 (1.6–3.0) <0.001
   Fluoroquinolone 107 (34) 174 (20) 2.1 (1.5–2.7) <0.001
   Trimethoprim/sulfamethoxazole 10 (3) 10 (1) 2.8 (1.2–6.8) 0.022
   Macrolide 22 (7) 39 (5) 1.6 (0.9–2.7) 0.101
   Lincosamide 18 (6) 19 (2) 2.7 (1.4–5.2) 0.004
   Glycopeptide 16 (5) 21 (2) 2.2 (1.1–4.2) 0.024
   Aminoglycoside 40 (13) 57 (7) 2.1 (1.4–3.2) 0.001
   Carbapenem 61 (19) 46 (5) 4.3 (2.9–6.5) <0.001
   First-generation cephalosporin 41 (13) 62 (7) 2.0 (1.3–3.0) 0.002
   Second-generation cephalosporin 70 (22) 132 (15) 1.6 (1.2–2.2) 0.003
   Extended-spectrum cephalosporin 137 (43) 205 (24) 2.5 (1.9–3.3) <0.001
History of intervention within three months
   Urinary catheterization 58 (18) 80 (9) 2.2 (1.5–3.2) <0.001
   Center catheter 18 (6) 32 (4) 1.6 (0.9–2.9) 0.140
   Intubation/tracheostomy 3 (1) 6 (1) 1.4 (0.3–5.6) 0.707
   Nasogastric tube 20 (6) 26 (3) 2.2 (1.2–4.0) 0.011
   Major surgery 13 (4) 16 (2) 2.3 (1.1–4.8) 0.032
Data are summarized as N (%), unless otherwise indicated.    
Bold formatting indicates statistical significance.    
Abbreviations: CO, community-onset; ESBL, extended-spectrum β-lactamase; EC, Escherichia coli; CI, confidence interval; OR, odds ratio, ICU, intensive 
care unit; IQR, interquartile range; LTCH, long-term care hospital; SOFA, sequential organ failure assessment.
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use of medical devices (such as a urinary catheter), recent use 
of antimicrobial agents, and comorbidities [6, 18, 19]. In this 
study, previous admission to a hospital, especially to an LTCH, 
and use of carbapenem, lincosamide, aminoglycoside, and ex-
tended-spectrum cephalosporin antimicrobials within the previ-
ous three months emerged as risk factors for ESBL-EC BSI, 
whereas medical procedures, such as urinary catheterization 
and use of nasogastric tubes, did not. Our results will assist in 
adjusting local recommendations for the appropriate empirical 
antimicrobial therapy of this unique population, in the sense 
that patients with these ESBL-EC infection risk factors would be 
considered for empirical therapy using antimicrobials with activ-
ity against ESBL producers.
The burden of infection and antimicrobial resistance in LTCHs 
is a significant threat to public health [20, 21]. The primary lo-
cation of antimicrobial resistant bacteria is tertiary-care hospi-
tals, but the frequent referral and transfer between acute-care 
hospitals and LCTHs in Korea has led to the spread of antimi-
crobial resistant bacteria to LTCHs [22, 23], which are particu-
larly vulnerable due to lack of effective infection control strate-
gies [24]. In this study, history of LTCH admission was strongly 
associated with CO ESBL-EC BSI (OR 3.8, 95% CI 2.3–6.1). 
Because the influx of ESBL-EC from LTCHs can cause out-
breaks in acute-care hospitals, appropriate barrier precautions 
and active surveillance cultures should be employed during pa-
tient transfer, according to cost-effectiveness evaluation find-
ings. In addition, further study on the current status of antimi-
crobial resistance in Korean LTCHs is urgently needed.
This multicenter study of six sentinel hospitals located across 
Korea showed that an alarmingly high proportion (27%) of CO 
EC-BSIs are caused by ESBL producers. Korea has experienced 
a significant increase in the proportion of ESBL producers 
among CO-BSI causing E. coli, with a 4.1% increase in 2002–
2005 [25] and 9.5% increase in 2006–2009 [7]. Continuous 
increase of antimicrobials use would increase the prevalence of 
resistant isolates; however, this correlation is not always obvious 
due to the complexity of resistance ecology [26]. Among the an-
timicrobials, previous use of carbapenem was most significantly 
associated with CO ESBL-EC BSI in both multivariate models 
(P <0.001). This suggests that increased use of carbapenem 
would increase ESBL producers. To prevent antimicrobial resis-
tance in the community, it is important to focus on antimicrobial 
stewardship and, in particular, on the proper use of carbape-
nem. Reducing the use of other antimicrobials, such as lincos-
amide, aminoglycoside, and extended-spectrum cephalosporin, 
will also contribute to preventing the spread of ESBL producers 
in Korea.
All ESBL-EC isolates had CTX-M-type genotypes, including 
CTX-M-15 (N=131), CTX-M-14 (N=86), CTX-M-27 (N=42), 
and CTX-M-55 (N=28). CTX-M-15 was the most common type 
among ESBL-EC from clinical blood isolates at Korean hospitals 
[27, 28]. CTX-M-55 can be rapidly disseminated and transmit-
ted in clinical practices in China [29] and is the most frequently 
detected ESBL-EC type of animal-origin in Korea [30, 31]. This 
reflects temporal trends in blaCTX-M epidemiology, showing that 
Table 2. Multivariate analysis of risk factors associated with com-
munity-onset E. coli bloodstream infection
Model OR (95% CI) P
Model with history of admission to any hospital
History of admission* 1.6 (1.1–2.2) 0.006
Previous use of antimicrobials
   Carbapenem 2.7 (1.7–4.3) <0.001
   Lincosamide 2.6 (1.3–5.3) 0.006
   Aminoglycoside 1.8 (1.1–2.7) 0.014
   Extended-spectrum cephalosporin 1.5 (1.1–2.2) 0.031
Model with history of admission to LTCH
History of admission to LTCH* 3.8 (2.3–6.1) <0.001
Previous use of antimicrobials
  β-lactam/β-lactamase inhibitor 1.4 (1.0–2.0) 0.039
   Carbapenem 2.9 (1.8–4.5) <0.001
   Lincosamide 2.6 (1.3–5.1) 0.008
   Aminoglycoside 1.8 (1.1–2.8) 0.015
   Extended-spectrum cephalosporin 1.7 (1.3–2.4) <0.001
   1st generation cephalosporin 1.5 (0.96–2.4) 0.075
Bold formatting indicates statistical significance.   
*These two variables were not analyzed simultaneously because of collinearity.
Abbreviations: LTCH, long-term care hospital; OR, odds ratio.










ST131 181 (57) 72 (8) 253 (21) <0.001
ST95 5 (2) 119 (14) 124 (10)
ST69 14 (4) 99 (11) 113 (10)
ST1193 17 (5) 56 (6) 73 (6)
ST73 0 62 (7) 62 (5)
ST38 13 (4) 27 (3) 40 (3)
Others 86 (27) 438 (50) 524 (44)
Data are summarized as N (%) of patients.    
Abbreviations: ST, sequence type; ESBL, extended-spectrum β-lactamase.
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blaCTX-M-15 and blaCTX-M-14 have displaced other genotypes in 
many parts of the world [32]. One isolate in our study had both 
CTX-M-15 and TEM-30.
The MLST results showed clonal diversity among EC isolates, 
but ST131 was the most common ESBL-EC type; hence, ST131 
is another risk factor of ESBL-EC. We previously reported that 
ST131 clones may be associated with the spread of community-
associated BSI exhibiting high antimicrobial resistance and 
highly virulent H30Rx traits [27]. In a multicenter study from 
Korea, the prevalence of ST131 isolates was 21% (57/268) [33]. 
ST131 can harbor CTX-M-14 and CTX-M-15 [27, 31] and was 
associated with hospital settings but now plays a major role in 
global dissemination as a pandemic clone, causing predomi-
nantly CO antimicrobial-resistant infection [34]. The reasons for 
the successful dissemination and expansion of the ST131 
clones remain unclear, but possible contributors include LTCH 
[35], mismatched antibiotic selection [36], and the expansion 
of fluoroquinolone resistance-associated subclones [37]. ESBL-
EC spread in communities has led to the increased use of car-
bapenems, which creates selection pressure for carbapenem 
resistance. In this superbug era, carbapenem-resistant Entero-
bacteriaceae ST131 warrants close attention with respect to its 
epidemiological success and high prevalence in community set-
tings. Among the 116 carbapenemase-producing strains col-
lected from 16 countries during 2008–2013, 41 (35%) were 
carbapenemase-producing ST131 E. coli isolates [38].
Many of these risk factors have already been identified in stud-
ies from other countries. However, similar studies are needed in 
other regions, because risk factors might show substantial geo-
graphic differences across the world, according to antimicrobial-
prescribing practices, rates of colonization in the population, 
and population density. The strength of this study is that we an-
alyzed CO-associated E. coli isolated in Kor-GLASS, based on 
the principles of representativeness, specialization, harmoniza-
tion, and localization. The clinical isolates and information from 
six sentinel hospitals represent four of nine provinces and two of 
seven metropolitan cities in Korea [12]. We also used HIRA 
claim data, which include almost all antimicrobials and medical 
procedures under the National Health Insurance, assuring ac-
curacy in data collection. In conclusion, the prevalence of 
ESBL-EC is increasing in communities, and 27% of CO EC-BSIs 
are caused by ESBL producers in Korea. Documented risk fac-
tors of CO ESBL-EC BSIs should be considered for empirical 
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